Provenienza dei contatti di primo grado di Keld Søndergaard
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
| Public Company | Biotechnology | 2 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Keld Søndergaard tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
Minervax ApS
 Minervax ApS Medical SpecialtiesHealth Technology Minervax ApS provides vaccine against streptococci. It utilizes fusion protein, which has proved to elicit good protective immunity. Its vaccine provides protective immunity against many clinically relevant GBS strains. The firm is engages in biotechnology, scientific and technical activities, and research and development. The company was founded in 2010 and is headquartered in Copenhagen, Denmark. | Medical Specialties | Founder | |
Invest in Skane AB
 Invest in Skane AB Miscellaneous Commercial ServicesCommercial Services Invest in Skane AB provides organization consulting services. The private company is based in Skane, Sweden. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| CYXONE AB | Pharmaceuticals: Major | Chief Executive Officer | |
| University of Lund | College/University | Doctorate Degree | |
| Lund University School of Economics & Management | College/University | Masters Business Admin | |
Edvince AB
 Edvince AB BiotechnologyHealth Technology Edvince AB engages in clinical research and development services. It operates as a biotech company that focuses on a new form of emergency treatment for stroke. The company was founded by Lars Ingvar Herbert Edvinsson in 2003 and is headquartered in Lund, Sweden. | Biotechnology | Chief Executive Officer | |
CanImGuide Therapeutics AB
 CanImGuide Therapeutics AB Pharmaceuticals: MajorHealth Technology CanImGuide Therapeutics AB develops cancer therapies. The firm is a biotechnological company that reverses cancer related immunosuppression. It manufactures the proprietary drug P28R, a peptide with two modes of actions. The company was founded on March 21, 2006 and is headquartered in Hollviken, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
| Immodulate Pharma AB | Chief Executive Officer |
Statistiche
Distribuzione geografica
| Svezia | 8 |
| Danimarca | 2 |
Settori
| Health Technology | 5 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Posizioni
| Chief Executive Officer | 4 |
| Director/Board Member | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Contatti più connessi
| Insiders | |
|---|---|
| Carl Magnus Högerkorp | 7 |
| Thomas Areschoug | 3 |
- Borsa valori
- Insiders
- Keld Søndergaard
- Connessioni Società
